I am removing the link to the ‘Here to Help’ program, a thinly-veiled piece of Reckitt Benckiser propaganda that does much more to harm the lives of opioid addicts than to improve them. The connection isn’t real complicated, but might take a moment or two of your concentration to understand.
I’ve written in the past about how RB profits from the misunderstandings about the value (or lack thereof) of naloxone, a chemical that turns generic buprenorphine at $0.25 per mg into the identically-acting drug Suboxone at $1 per mg. I’ve written about RB’s mad rush to promote Suboxone film, to replace the profits expected to disappear as generic buprenorphine/naloxone enters the market. And I’ve written about the latest stunt by RB of declaring their own tablets unsafe shortly after their patent expired, essentially eliminating the ‘risk’ that affordable generic ‘Suboxone’ will ever reach suffering addicts.
The impact of RB’s actions extend beyond raising the price of their signature product– an action that by itself costs untold lives. The hyped concern over the safety of buprenorphine also strongly impacts the debate over raising the 100-patient limit faced by current providers. That means the doctors like me, with a waiting list of 80 people, must reconcile the wait list with obituaries as they appear in the paper each week– rather than treat those in need. But to RB, the most important thing isn’t to open more doors to treatment, but rather that the film be successful.